NovaVive

NovaVive Inc. was founded in July 2014 by Graeme McRae (Founder and Chairman Emeritus of Bioniche Life Sciences Inc.) as a private company to introduce scientifically rational immunobiology-based technologies that address unmet veterinary medical needs. NovaVive has also acquired the global license for MCNA to treat animal cancer. MCNA is an advanced formulation of mycobacterial cell wall and nucleic acid designed for human application. MCNA has been advanced by Bioniche Life Sciences Inc. into Phase III for the treatment of human bladder cancer.